Program - Brisbane Immunotherapy 2019

The program below may still be subject to further changes as arrangements with speakers are finalised.

THURSDAY - 23rd May 2019

07:30-17:00 Registration Desk Open

08:30 Welcome and Acknowledgements

09:00-10:00 Session I: Keynote Lecture

10:00-10:30 Morning Tea

10:30-12:05 Session II: Immunotherapy for autoimmune diseases

Location: Boulevard Auditorium

Chair: Professor Ranjeny Thomas

10:30-11:00
Professor Qizhi Tang, Director, UCSF Transplantation Research Lab, Department of Surgery, University of California, San Francisco - Translating regulatory T cell therapy to the clinic

11:00-11:20
Dr Emma Hamilton-Williams, The University of Queensland Diamantina Institute - Antigen-specific immunotherapy for type 1 diabetes

11:20-11:35
Dr Anne-Sophie Bergot, The University of Queensland Diamantina Institute - Regulatory T cells induced following single antigen immunotherapy suppress islet-specific T cell responses to multiple antigens and protect from autoimmune diabetes

11:35-11:50
Pascale Wehr, The University of Queensland Diamantina Institute - Arthritogenic clonally-expanded autoantigen-specific CD4+ T cells are a target for prevention of autoimmune arthritis

11:50-12:05
Aimee Hanson, The University of Queensland Diamantina Institute - T-cell receptor immunosequencing reveals disease-associated clonal expansions and altered repertoire diversity in ankylosing spondylitis patients

12:05-13:15 Lunch

13:15-14:50 Session III: Immunotherapy and the tumour microenvironment

Location: Boulevard Auditorium

Chair: Dr Tobias Bald

13:15-13:45
Professor Matthew Krummel, Department of Pathology, University of California San Francisco (UCSF) - Disseminating Tumor-Self via A Synaptic Cellular ‘Mancala`

13:45-14:05
Associate Professor Thomas Gebhardt, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity - Tissue-resident memory T cells promote melanoma-immune equilibrium in skin

14:05-14:20
Dr Ailin Lepletier, QIMR Berghofer Medical Research Institute - Tumor-intrinsic CD155 expression limits sensitivity to anti-PD-1 therapy in advanced metastatic melanoma

14:20-14:35
Diana Canals-Hernaez, The Biomedical Research Centre, University of British Columbia, Canada - Podocalyxin is a therapeutic target in carcinoma

14:35-14:50
Alvaro Sanchez-Herrero, Institute of Health & Biomedical Innovation, Queensland University of Technology - Tissue engineering of an orthotopic humanised bone-organ as a platform for preclinical multiple myeloma research

14:50-15:30 Afternoon Tea

15:30-17:00 Session IV: Adoptive immunotherapies

Location: Boulevard Auditorium

Chair: Associate Professor Corey Smith and Dr Ashleigh Poh

15:30-16:00
Dr Emily Blyth, Westmead Clinical School, The Westmead Institute for Medical Research and Westmead Hospital - BMT Cell Therapies, Sydney - The way forward for antigen-specific T cells for immune reconstitution – stem cell donors or third party cell banks?

16:00-16:20
Dr Paulo Martins, Tumour Immunology Group, QIMR Berghofer Medical Research Institute - Serotherapy prevents cytomegalovirus reactivation after transplantation

16:20-16:35
Associate Professor Corey Smith, QIMR Berghofer Medical Research Institute - Restructuring of the TRBV landscape is coincident with clinical response to T cell therapy in transplant recipients

16:35-16:50
Simone Minnie, QIMR Berghofer Medical Research Institute - Stem cell transplantation establishes T cell-dependent myeloma immune-equilibrium that can be enhanced with immunotherapy

16:50-17:05
Dr Matthias Braun, QIMR Berghofer Medical Research Institute - Loss of DNAM-1 on CD8⁺ T cells: a novel immune escape mechanism

17:00-19:00 Poster Session I / Welcome Reception

19:00-20:00 Public Forum

FRIDAY - 24th May 2019

08:00-17:00 Registration Desk Open

08:30-09:30 Session V: Keynote Lecture

09:30-09:50 Session VI: Adenosine: the new kid on the block

Location: Boulevard Auditorium

Chair: Associate Professor Michele Teng

09:30-09:50
Associate Professor John Stagg, CRCHUM and Institute of Cancer, University of Montreal - Targeting CD73 in cancer immunotherapy: beyond adenosine inhibition

09:50-10:10
Dr Courtney Beers, Vice President, Immunology, Tizona Therapeutics, San Francisco - Targeting CD39 with a First-in-Class Inhibitory Antibody Prevents ATP Processing and Increases T-Cell Activation

10:10-10:30
Dr Pam Holland, Vice President, Cancer Biology, Surface Oncology, Cambridge - Targeting the Adenosine Axis to Treat Cancer

10:30 Morning Tea

11:00-12:30 Session VII: Immunogenomics

Location: Boulevard Auditorium

Chair: Dr Nic Waddell

11:00-11:30
Dr Jinmiao Chen, Single-Cell Computational Immunology (SCCI), Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore - Single-cell analysis of crosstalk between tumor, immune cells and pathogens in gastric cancer

11:30-11:45
Dr Ann-Marie Patch, Head of Clinical Genomics Group, QIMR Berghofer Medical Research Institute - Bridging the fields of cancer genomics and Immunotherapy

11:45-12:00
Dr Andreas Behren, Biomedicine Discovery Institute, Monash University - The immunopeptidome of melanoma

12:00-12:15
Dr Simon Junankar, Garvan Institute of Medical Research - DNA barcoding demonstrates immuno-editing of metastatic breast cancer cells at the clonal level

12:15-12:30
Dr Jessica Engel, QIMR Berghofer Medical Research Institute - Mapping the Development of Gut Pathogenic CD4+ T-cells during Graft-versus-Host Disease using single-cell RNA-seq

12:30-13:30 Lunch

13:30-15:05 Session VIII: Innate immune cells in cancer immunotherapy

Location: Boulevard Auditorium

Chair: Dr Tobias Bald

13:30-14:00
Dr Jan Böttcher, Institute of Molecular Immunology and Experimental Oncology, Technical University Munich - The role of cDC1/NK cell communication within the tumor microenvironment for anti-cancer immunity

14:00-14:20
Dr Tatyana Chtanova, Innate and Tumour Immunology, Garvan Institute of Medical Research - Innate immune cells in cancer: Teaching neutrophils new tricks

14:20-14:35
Juming Yan, QIMR Berghofer Medical Research Institute - Title TBC

14:35-14:50
Associate Professor Eynav Klechevsky, Washington University School of Medicine, St. Louis - Upstream activation of anti-tumor immunity via human dendritic cell subsets

14:50-15:05
Amanda Oliver, Peter MacCallum Cancer Centre - Tissue-specific differences in the tumour microenvironment and their influence on immunotherapeutic response

15:05-15:30 Afternoon Tea

15:30-16:00 Session IX: The Microbiome: an emerging universe

Location: Boulevard Auditorium

Chair: Associate Professor Antiopi Varelias

15:30-16:00
Dr Beth Helmink, Department of Surgical Oncology and Genomic Medicine, University of Texas MD Anderson Cancer Centre - Bringing concepts to clinic: the gut microbiome and the response to and toxicity of immune checkpoint blockade in melanoma

16:00-16:20
Professor Emad El-Omar, Director, Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales - The role of the microbiome in GI cancer

16:20-16:40
Dr Nadeem Kaakoush, Head of Host-Microbiome Interactions Group, School of Medical Sciences, University of New South Wales, Sydney - Microbiome manipulation through faecal microbiota transplantation therapy

16:40-18:05 Session X: Immunotherapy and infectious diseases

Location: Boulevard Auditorium

Chair: Dr Janin Chandra

18:40-17:10
Professor Man-Wah Tan, Infectious Diseases Therapeutic Area, Genentech, San Francisco, California - Harnessing nature’s gift: antibody and antibody-antibiotic conjugates to treat bacterial infections

17:10-17:30
Dr Keith Chappell, School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland - Rapid response pipeline for stabilized subunit vaccines

17:30-17:50
Dr Christian Engwerda, QIMR Berghofer Medical Research Institute - Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of malaria and visceral leishmaniasis.

17:50-18:05
Dr Manisha Pandey, Institute for Glycomics, Griffith University - Immunotherapy with antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA humanized mice

18:05-19:30 Poster Session II / Light Refreshments

SATURDAY - 25th May 2019

08:00-14:00 Registration Desk Open

09:00-10:30 Session XI: Plenary Session: Neoadjuvant immunotherapy - a game changer?

Location: Boulevard Auditorium

Chair: Dr Elizabeth Ahern

09:00-10:00
Professor Christian Blank, Department of Medical Oncology & Division of Immunology, Netherlands Cancer Institute– Antoni van Leeuwenhoek Hospital, Amsterdam - Neoadjuvant Immunotherapy – the pathway to personalized immunotherapy in melanoma and beyond

10:00-10:30
Associate Professor Michele Teng, Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute - Neoadjuvant immunotherapy and surgery – a window of opportunity for tumor-specific T cell memory differentiation

10:30-11:00 Morning Tea

11:00-12:45 Session XII: CAR-T cells: Beyond blood cancers

Location: Boulevard Auditorium

Chair: Dr Siok Tey

11:00-11:30
Professor Stephen Gottschalk, Dept. of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Hospital - Engineering Lymphocytes for the Adoptive Immunotherapy of Solid Tumors

11:30-11:50
Professor Simon Barry, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide - Title TBC

11:50-12:05
Dr Blake Aftab, Preclinical and Translational Sciences, Atara Biotherapeutics - CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T cells – An Off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform

12:05-12:20
Professor Riccardo Dolcetti, The University of Queensland Diamantina Institute - Enhancing CAR-T cell immunotherapy against solid tumours by exploiting nanoemulsion-based indirect vaccination

12:20-12:35
Jessica Michie, Peter MacCallum Cancer Centre - Antagonism of IAPs enhances CAR T cell efficacy

12:45-14:00 Lunch

14:00-15:20 Session XIII: Clinical immuno-oncology

Location: Boulevard Auditorium

Chair: Dr Andrea Henden

14:00-14:20
Associate Professor Victoria Atkinson, School of Clinical Medicine, The University of Queensland and Medical Oncologist, Princess Alexandra and Greenslopes Private Hospitals, Brisbane - Modern Immunotherapy for advanced melanoma

14:20-14:40
Professor Sandro Porceddu, Director Radiation Oncology Research, Cancer Services, Princess Alexandra Hospital and Faculty of Medicine, University of Queensland - The evolution and role of immunotherapy in head and neck cancer

14:40-15:00
Professor Ken O’Byrne, Medical Oncologist, Princess Alexandra Hospital, Queensland University of Technology, Translational Research Institute - Title TBC

15:00-15:20
Dr Alistair Cook, Research Fellow, Faculty of Health and Medical Sciences, UWA Medical School, The University of Western Australia - Results of a phase 2 trial of DuRvalumab with first line chEmotherApy in Mesothelioma (DREAM)

15:20-15:50 Award Presentations and Closing Remarks